IL292693B1 - Mrgprx2 antagonists and their uses - Google Patents

Mrgprx2 antagonists and their uses

Info

Publication number
IL292693B1
IL292693B1 IL292693A IL29269322A IL292693B1 IL 292693 B1 IL292693 B1 IL 292693B1 IL 292693 A IL292693 A IL 292693A IL 29269322 A IL29269322 A IL 29269322A IL 292693 B1 IL292693 B1 IL 292693B1
Authority
IL
Israel
Prior art keywords
compound
alkyl
optionally substituted
composition
skin
Prior art date
Application number
IL292693A
Other languages
English (en)
Hebrew (he)
Other versions
IL292693A (en
Original Assignee
Dermirainc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dermirainc filed Critical Dermirainc
Publication of IL292693A publication Critical patent/IL292693A/en
Publication of IL292693B1 publication Critical patent/IL292693B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL292693A 2019-11-05 2020-11-05 Mrgprx2 antagonists and their uses IL292693B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962931186P 2019-11-05 2019-11-05
US201962931576P 2019-11-06 2019-11-06
US202063046481P 2020-06-30 2020-06-30
PCT/US2020/059228 WO2021092264A1 (en) 2019-11-05 2020-11-05 MrgprX2 ANTAGONISTS AND USES THEREOF

Publications (2)

Publication Number Publication Date
IL292693A IL292693A (en) 2022-07-01
IL292693B1 true IL292693B1 (en) 2026-05-01

Family

ID=73740488

Family Applications (1)

Application Number Title Priority Date Filing Date
IL292693A IL292693B1 (en) 2019-11-05 2020-11-05 Mrgprx2 antagonists and their uses

Country Status (8)

Country Link
US (1) US20230002336A1 (cg-RX-API-DMAC7.html)
EP (1) EP4055011A1 (cg-RX-API-DMAC7.html)
JP (1) JP7787811B2 (cg-RX-API-DMAC7.html)
CN (1) CN114728919B (cg-RX-API-DMAC7.html)
AU (1) AU2020380926B2 (cg-RX-API-DMAC7.html)
CA (1) CA3159633A1 (cg-RX-API-DMAC7.html)
IL (1) IL292693B1 (cg-RX-API-DMAC7.html)
WO (1) WO2021092264A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115850094B (zh) * 2022-09-07 2025-02-11 北华航天工业学院 一种利用1,2-环氧丁烷合成β-氨基醇的方法
WO2025002360A1 (zh) * 2023-06-30 2025-01-02 北京普祺医药科技股份有限公司 一种mrgprx2拮抗剂、药物组合物以及其用途
US20250084063A1 (en) 2023-08-18 2025-03-13 Incyte Corporation Bicyclic heterocycles as mrgprx2 antagonists
WO2025160430A1 (en) 2024-01-25 2025-07-31 Incyte Corporation Bicyclic heterocycles as mrgprx2 antagonists
WO2025163462A1 (ko) * 2024-02-02 2025-08-07 삼진제약주식회사 헤테로고리를 갖는 mrgprx2((mas-related g-protein coupled receptor member x2) 길항제 유도체와 이의 용도
WO2025222076A1 (en) 2024-04-19 2025-10-23 Kyorin Pharmaceutical Co., Ltd. 1h-pyrrolo[2,3-b]pyridine derivatives as mrgprx2 antagonists for the treatment of inflammatory diseases
WO2025222040A1 (en) 2024-04-19 2025-10-23 Escient Pharmaceuticals, Inc. Mrgprx2 modulators for use in treating mrgprx2 dependent conditions in subjects with low ige
US12630562B2 (en) 2024-08-07 2026-05-19 Arcus Biosciences, Inc. Piperidylurea compounds and methods of use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4158659A (en) * 1975-06-05 1979-06-19 Lilly Industries Limited Acylamino derivatives
WO2004089415A2 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST
US20090163545A1 (en) * 2007-12-21 2009-06-25 University Of Rochester Method For Altering The Lifespan Of Eukaryotic Organisms
WO2015089327A1 (en) * 2013-12-11 2015-06-18 Biogen Idec Ma Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
US20160096834A1 (en) * 2014-10-06 2016-04-07 Merck Patent Gmbh Heteroaryl compounds as btk inhibitors and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
EP0084665B1 (de) * 1982-01-22 1986-08-13 BASF Aktiengesellschaft Thiadiazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Bekämpfung unerwünschten Pflanzenwuchses
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
GB0308511D0 (en) * 2003-04-14 2003-05-21 Astex Technology Ltd Pharmaceutical compounds
BRPI0413709A (pt) * 2003-08-21 2006-10-17 Pfizer Prod Inc compostos para o tratamento de distúrbios neurodegenerativos
DE102004009933A1 (de) * 2004-02-26 2005-09-15 Merck Patent Gmbh Verwendung von Thiadiazolharnstoffderivaten
EP2125799A1 (en) 2007-02-28 2009-12-02 Smithkline Beecham Corporation Thiadiazole derivatives, inhibitors of stearoyl-coa desaturase
EP2725022B1 (de) * 2008-06-13 2017-03-29 Bayer CropScience AG Neue Amide als Schädlingsbekämpfungsmittel
WO2010073011A2 (en) * 2008-12-23 2010-07-01 Betagenon Ab Compounds useful as medicaments
US8377639B2 (en) * 2009-06-26 2013-02-19 University Of Massachusetts Compounds for modulating RNA binding proteins and uses therefor
RU2601550C2 (ru) * 2010-12-09 2016-11-10 Вокхардт Лимитед Кетолидные соединения
JP6130383B2 (ja) * 2011-09-30 2017-05-17 エンドゥ ファーマシューティカルズ,インコーポレイティド ピリジン誘導体
CN104955332B (zh) * 2013-01-30 2017-03-29 住友化学株式会社 防治节足害虫的方法
BR112019018230A2 (pt) * 2017-03-02 2020-07-21 Assembly Biosciences, Inc. compostos de sulfamida cíclica e métodos de sua utilização

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4158659A (en) * 1975-06-05 1979-06-19 Lilly Industries Limited Acylamino derivatives
WO2004089415A2 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST
US20090163545A1 (en) * 2007-12-21 2009-06-25 University Of Rochester Method For Altering The Lifespan Of Eukaryotic Organisms
WO2015089327A1 (en) * 2013-12-11 2015-06-18 Biogen Idec Ma Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
US20160096834A1 (en) * 2014-10-06 2016-04-07 Merck Patent Gmbh Heteroaryl compounds as btk inhibitors and uses thereof

Also Published As

Publication number Publication date
CN114728919B (zh) 2025-12-30
AU2020380926B2 (en) 2026-07-16
AU2020380926A1 (en) 2022-05-26
CA3159633A1 (en) 2021-05-14
WO2021092264A1 (en) 2021-05-14
IL292693A (en) 2022-07-01
JP2022554392A (ja) 2022-12-28
CN114728919A (zh) 2022-07-08
US20230002336A1 (en) 2023-01-05
EP4055011A1 (en) 2022-09-14
JP7787811B2 (ja) 2025-12-19

Similar Documents

Publication Publication Date Title
IL292692B1 (en) Mrgprx2 antagonists and their uses
IL291244A (en) hpk1 antagonists and uses thereof
IL294052B2 (en) Fluoroalkyl oxadiazoles and their uses
IL275463A (en) TLR7/8 antagonists and their use
IL285177A (en) compounds and their use
GB201905552D0 (en) Antagonists
IL286497A (en) compounds and their use
IL277502A (en) Compounds and uses for them
SG11202100818RA (en) Tlr7/8 antagonists and uses thereof
IL280808A (en) OX40-binding polypeptides and their uses
GB2603645B (en) Polypeptides having anti-senescent effects and uses thereof
IL292693A (en) Mrgprx2 antagonists and uses thereof
IL287782A (en) Cd33-binding polypeptides and uses thereof
SG11202103021VA (en) Cd40l antagonist and uses thereof
IL274751A (en) ILDR2 antagonists and combinations thereof
ZA202101406B (en) Integrin antagonists
IL291499A (en) Azaquinoline compounds and their uses
GB201815629D0 (en) Antagonists
IL269836B (en) Converted N-arylethyl-2-aminoquinoline-4-carboxamides and their use
IL287503A (en) Thio-semicarbazide compounds and their use
IL284764A (en) compounds and their uses
IL279483A (en) Cyanotriazole compounds and their uses
GB201819200D0 (en) Polypeptide and uses thereof
IL288828A (en) Binding factors - cd38 and their use
IL313687A (en) OXER1 antagonists and their uses